Loading…
Sectoral / Thematic · quant Mutual Fund · AMFI code 151853quant Healthcare Fund
Disclosed for 38 months, Aug 2023 to Sep 2026.
Portfolio value
₹236 Cr
up ₹44.7 Cr vs Dec 2023
- Stocks held
- 14
- up 2 vs Dec 2023
- Top 10 weight
- 70.6%
- of the portfolio in its ten largest
- Cash & debt
- 5.8%
- cash, money market and debt
- Moves this month
- 3 in · 1 out
quant Healthcare Fund is an active equity fund in the Sectoral / Thematic category from quant Mutual Fund. In January 2024 it disclosed 14 stocks worth ₹236 Cr, up ₹44.7 Cr from Dec 2023. Its largest positions were Life Insurance Corporation Of India (9.8%), Reliance Industries Limited (9.8%), Sun Pharmaceutical Industries Limited (8.0%); the ten largest together made up 70.6% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 58.1% of its equity. Cash and debt stood at 5.8%. Compared with Dec 2023 the fund entered 3 new stocks and exited 1.
Against 229 other Sectoral / Thematic funds
Concentration
94%
Top-10 weight is higher than 94% of peers
Breadth
2%
Holds more stocks than 2% of peers
Cash
77%
Holds more cash than 77% of peers
What these mean: concentration · cash
Holdings in January 2024
Download CSVEvery line the fund disclosed, with the change against Dec 2023. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Life Insurance Corporation Of India | 9.85% | up 0.51 pts | ₹23.3 Cr | up ₹5.4 Cr | Added |
| Reliance Industries Limited | 9.82% | up 0.25 pts | ₹23.2 Cr | up ₹4.9 Cr | Added |
| Sun Pharmaceutical Industries Limited | 7.95% | down 0.76 pts | ₹18.8 Cr | up ₹2.1 Cr | Added |
| Biocon Limited | 7.95% | up 7.95 pts | ₹18.8 Cr | up ₹18.8 Cr | New |
| Aurobindo Pharma Limited 29/02/2024 Derivative | 7.14% | up 7.14 pts | ₹16.9 Cr | up ₹16.9 Cr | New |
| Lupin Limited 29/02/2024 Derivative | 6.80% | up 6.80 pts | ₹16.1 Cr | up ₹16.1 Cr | New |
| Jubilant Pharmova Limited | 6.04% | up 1.78 pts | ₹14.3 Cr | up ₹6.1 Cr | Added |
| Sequent Scientific Limited | 5.66% | up 0.50 pts | ₹13.4 Cr | up ₹3.5 Cr | Added |
| Indoco Remedies Limited | 5.05% | down 1.56 pts | ₹11.9 Cr | down ₹73 L | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 4.38% | down 5.62 pts | ₹10.3 Cr | down ₹8.8 Cr | Trimmed |
| Suven Life Sciences Limited | 3.80% | up 3.80 pts | ₹9 Cr | up ₹9 Cr | New |
| Granules India Limited | 3.69% | down 0.75 pts | ₹8.7 Cr | up ₹22 L | Added |
| Aarti Pharmalabs Limited | 3.63% | down 0.21 pts | ₹8.6 Cr | up ₹1.2 Cr | Added |
| AstraZeneca Pharma India Limited | 3.25% | down 0.10 pts | ₹7.7 Cr | up ₹1.3 Cr | Added |
| Apollo Hospitals Enterprise Ltd 29/02/2024 Derivative | 3.04% | up 3.04 pts | ₹7.2 Cr | up ₹7.2 Cr | New |
| BROOKS Laboratories Limited | 3.03% | down 0.59 pts | ₹7.2 Cr | up ₹22 L | Added |
| Poly Medicure Limited | 2.16% | up 2.16 pts | ₹5.1 Cr | up ₹5.1 Cr | New |
| 91 Days Treasury Bill 14-Mar-2024 Debt | 2.10% | down 0.47 pts | ₹5 Cr | up ₹3 L | Added |
| 91 Days Treasury Bill 02-May-2024 Debt | 2.08% | up 2.08 pts | ₹4.9 Cr | up ₹4.9 Cr | New |
| Cash, TREPS & receivables | 1.63% | down 2.08 pts | ₹3.8 Cr | down ₹3.3 Cr | Trimmed |
| Sun Pharmaceutical Industries Limited 29/02/2024 Derivative | 0.96% | up 0.96 pts | ₹2.3 Cr | up ₹2.3 Cr | New |
What changed, Dec 2023 to Jan 2024
New New positions (3)
- Biocon Limited7.9% · ₹18.8 Cr
- Suven Life Sciences Limited3.8% · ₹9 Cr
- Poly Medicure Limited2.2% · ₹5.1 Cr
Exited Exited (1)
- Aster DM Healthcare Limitedwas 9.1% · ₹17.4 Cr
Added Biggest additions
- Jubilant Pharmova Limitedup ₹6.1 Cr (+1.78% pts)
- Life Insurance Corporation Of Indiaup ₹5.4 Cr (+0.51% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Dec 2023, the weight rose most in Pharmaceuticals & Biotechnology (+4.6 pts) and Healthcare Equipment & Supplies (+2.9 pts), and fell most in Healthcare Services (−7.0 pts) and Pharmaceuticals (−2.0 pts).
- Pharmaceuticals & Biotechnology53.5% → 58.1%+4.6 pts
- Healthcare Equipment & Supplies0.0% → 2.9%new+2.9 pts
- Insurance12.6% → 13.4%+0.9 pts
- Petroleum Products12.9% → 13.4%+0.5 pts
- Healthcare Services12.2% → 5.2%−7.0 pts
- Pharmaceuticals8.9% → 6.9%−2.0 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Oct 2023 | Dec 2023 | Jan 2024 |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 55.2% | 53.5% | 58.1% |
| Insurance | — | 12.6% | 13.4% |
| Petroleum Products | 13.2% | 12.9% | 13.4% |
| Pharmaceuticals | 8.3% | 8.9% | 6.9% |
| Healthcare Services | 11.8% | 12.2% | 5.2% |
| Healthcare Equipment & Supplies | 11.5% | — | 2.9% |
Allocation in Jan 2024change vs Dec 2023
- Pharmaceuticals & Biotechnology (8)58.1%▲ 4.6 pts
- Insurance (1)13.4%▲ 0.9 pts
- Petroleum Products (1)13.4%▲ 0.5 pts
- Pharmaceuticals (1)6.9%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Jan 2024
5.8%
▼ 0.5 pts vs Dec 2023
- Cash alone
- 1.6%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- 0.5% – 6.3%
- lowest to highest · record 6.3% in Dec 2023
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.